Mobile Health Monitoring Solution for Heart Failure Patients

NCT ID: NCT02594007

Last Updated: 2017-07-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-30
• Study Completion Date: 2017-01-31

Brief Summary

Heart Failure (HF) affects 5.7 million Americans and is the only major cardiovascular disorder on the rise. The primary aim of this study is to formally study the combined effects of several different tele-health modalities, all currently approved and available for general use, to determine if such combinations will result in an increase in early intervention and a resultant decrease in acute cardiac decompensation requiring a hospitalization or Emergency Room (ER) visit. This study will attempt to characterize the frequency of health care interventions attributable to the use of these technologies, and any relationship between these interventions and the frequency of hospitalization or ER visits.

Secondary objectives include characterization of healthcare utilization, healthcare costs, and patient experiences with regard to the use the provided technologies.

Detailed Description

It is estimated that 400,000 to 700,000 new cases of heart failure (HF) are diagnosed each year and the number of deaths in the United States from this chronic condition has more than doubled since 1979 - averaging 275,000 annually. HF accounts for over 1.1 million annual hospital discharges, 3.4 million physician office visits, 668,000 emergency department visits, and 293,000 outpatient visits per year. The economic impact is equally staggering: the total estimated annual cost of heart failure exceeds $40 billion. This figure is expected to reach $97 billion by 2030. While initial hospitalizations consume a vast amount of health care resources, readmissions are also a significant problem. The overall readmission rate (all cause) in the United States is 19.6%. Studies have shown the 30-day readmission rate for HF to be 24%. The important clinical implication is that patients are particularly vulnerable in the early post-discharge period (30-90 days from hospital to home) and require heightened surveillance, especially if the hospital admission has been prolonged or if the patient has had prior admissions for worsening HF. Despite advances in pharmacologic and monitoring device therapy, the inability to effectively manage and influence patient behavior and the inability of patients to identify signs and symptoms of decompensated HF are major hurdles to improving outcomes and avoiding subsequent readmissions. Less than 10% of HF patients are eligible for implantable monitoring devices due to a variety of reasons. Non-invasive cardiac telemetry units only monitor a patient's echocardiograph (ECG). HF patients present with numerous other physiologic parameters which largely go unmonitored and changes in status undetected after discharge from hospital to home. A worsening status in any one of these indicators may predict worsening condition or decompensation. This gap leaves a tremendous percentage (the majority, in fact) of the HF population at risk for repeat medical crisis and re-hospitalizations.

Managing the HF patient population requires highly skilled clinicians, stringent monitoring and care coordination, and advanced technology integration. The investigators propose a patient-centered non-invasive remote monitoring care system for HF. This model leverages three distinct technology platforms. This unique care plan brings together physiologic data capture with symptomatic and behavioral patient information into a dynamic patient engagement and education mobile platform that analyzes, predicts and notifies clinicians when a patient's baseline health is changing before it leads to a negative health consequence and subsequent hospital re-admission or ER visit.

1. A small cutaneous Mobile Patient Monitoring patch (SEEQ®) from Medtronic that continuously collects ECG data, plus heart rate, heart rate variability, respiratory rate, and atrial fibrillation status. These added physiologic parameters provide clinicians more precise insight into a patient's condition and clearly differentiates the monitoring technology from standard approaches. The Medtronic patch is applied like a band-aid to the patient's chest prior to hospital discharge. As it collects data, the information is wirelessly transmitted via Bluetooth to a patient care platform from which providers can access information in live-time for 30 days post discharge. Medtronic's patch does not require leads like other commercially available systems, and does not need to be removed during bathing and other normal activities. Thus this product increases patient compliance and enhances satisfaction. An increase in patient compliance will ensure a more complete and accurate picture of the patient's health. Captured data is used to 1) provide clinicians with physiological data for patients who are at risk of near-term decompensated HF, and 2) allow clinicians to deliver live-time treatment intervention and guidance from anywhere at any time, preventing health problems from escalating into health crises.

Another key differentiator in this care model is the patient's use of a tablet-based tele-health mobile software application that includes the patient's discharge plan, a daily medication management list, reminders, and CHAT features for live, interactive communication with the care team. The software assesses the patient's psychosocial status and enables clinicians to coach and guide patients to change negative health behaviors and adhere to their care plan.

2. Medtronic's Cardiocom system deploys a proprietary cellular-based patient interface tool (Commander Flex), a blood pressure cuff that interfaces directly with the Commander Flex and a Bluetooth enabled medical-grade scale that also interfaces directly with the Commander Flex. The patient is required to take the blood pressure and weight measurements at prescribed intervals over the evaluation period (30 days) as well as answer a variety of behavioral and symptomatic questions that operate on a proprietary tree-based questioning algorithm.

3. Docview® mHealth solution encourages self-management and empowers patients to become stakeholders in their health. The application collects real-time data with regular "check-ins" to analyze state of wellness, and enables patients to connect live with their care team - no matter where they are. The entire process takes less than one minute to complete and the answers provide the care team an actionable risk-stratification snapshot. Automating the process allows larger patient populations to be monitored, yet drastically reduces provider-patient involvement, as only at-risk patients need to be notified (10-15% estimated). In a traditional setting, the monitoring team typically calls every patient and could maintain a caseload of only 20-25 patients (average call time 20-25 min). All patients have to be contacted by phone just to determine if a risk exists. The proposed tele-health solution uses real-time data analysis and predictive modeling to proactively notify a provider that a patient's baseline health is changing prior to a negative health issue, and quickly delivers an intervention to the patient based on clinical decisions and statistically validated treatment algorithms.

This unique care plan brings together physiologic data capture with symptomatic and behavioral patient information into a dynamic patient engagement and education mobile platform that analyzes, predicts and notifies clinicians when a patient's baseline health is changing before it leads to a negative health consequence and subsequent hospital re-admission or ER visit.

Conditions

Heart Failure

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

discharge home

SEEQ for 28 days. Cardiocom for 30 days

Group Type: EXPERIMENTAL

SEEQ

Intervention Type: DEVICE

Mobile cardiac telemetry system worn externally for a total of 28 days.

Cardiocom

Intervention Type: DEVICE

Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.

discharge to skilled nursing facility

SEEQ for 28 days, DocView for 30 days

Group Type: EXPERIMENTAL

SEEQ

Intervention Type: DEVICE

Mobile cardiac telemetry system worn externally for a total of 28 days.

DocView

Intervention Type: DEVICE

Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.

Interventions

SEEQ

Mobile cardiac telemetry system worn externally for a total of 28 days.

Intervention Type: DEVICE

Cardiocom

Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.

Intervention Type: DEVICE

DocView

Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Admitted patients to Morristown Medical Center located on Gagnon 1 Heart Failure (HF) dedicated unit with an anticipated Discharge DRG of HF

2. Subjects with acute decompensated HF

3. Subject > 55 years of age

4. Subject meets the indications for the use of the external patch

5. Subject is able and willing to provide informed consent

Exclusion Criteria

1. Subjects with an implantable cardiac device or scheduled to receive a cardiac device within 30 days of enrollment

2. Skilled Nursing Facility (SNF) bound patients who are unwilling/unable to receive care at CareOne Madison

3. Subject with a scheduled readmission within 30 days of discharge

4. Subjects weighing > 500 lbs

5. Subjects with potentially life-threatening arrhythmias, or who require inpatient/hospital monitoring

6. Subject who is expected to receive a heart transplant or a ventricular assist device within 6 months of enrollment

7. Subject with known allergies or hypersensitivities to adhesives or hydrogels

8. Subject who cannot tolerate placement of external patch monitor on chest in the proposed location (electrocardiogram lead II orientation)

9. Subject who will not comply with project protocol requirements (i.e. Docview/Cardiocom engagement). This includes completing required data collection, and attending required follow up visits

10. Prior enrollment in this study

11. Subjects who are pregnant

12. Subjects who are non-English speaking.

• Minimum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Atlantic Health System

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nancy Bonnet, APNc MSN RN

Role: PRINCIPAL_INVESTIGATOR

Morristown Medical Center

Locations

Morristown Medical Center

Morristown, New Jersey, United States

Countries

United States

Related Links

http://www.ncbi.nlm.nih.gov/m/pubmed/20610207/

HFSA 2010 Comprehensive Heart Failure Practice Guideline

Other Identifiers

774885-1

Identifier Type: -

Identifier Source: org_study_id